Bio Pharma Dive

FEBRUARY 15, 2024

The partnership will use Intellia's "DNA writing” technology, and initially focus on people with the lung disease who have limited or no available treatment options.

Genetics 171

Genetics Medicine DNA 171

Bio Pharma Dive

AUGUST 9, 2023

Third Rock-founded Decibel, which has shed much of its value since a 2021 IPO, expected to run out of money within a year.

Genetics 245

Genetics Medicine 245

Pharmaceutical Technology

FEBRUARY 13, 2024

The MHRA kicks off phase two of the Yellow Card biobank to explore the genetic link to side effects of direct oral anticoagulants.

Biobanking 277

Biobanking Medicine Genetics 277

Drug Discovery World

JUNE 8, 2023

He focuses on enhancing genetically guided personalised medicine with the goal of providing safer and more effective therapies that are accessible to everyone. The post Enhancing genetically guided personalised medicine appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Medicine Drugs Development 52

Bio Pharma Dive

JUNE 29, 2022

The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.

Genetics 252

Genetics Medicine Development 252

Drug Discovery World

FEBRUARY 16, 2023

Challenges remain with current delivery approaches, and genetic medicines applications have been generally restricted to the liver and ex vivo settings. The post Start-up aims to advance transformative genetic medicines appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Medicine Gene Editing In-Vivo 52

Scienmag

APRIL 14, 2022

In a Policy Forum, Anna Lewis and colleagues argue that, for researchers and others who want to invoke genetic ancestry, there is a scientific and ethical imperative to move away from continental ancestry categories and to instead embrace a view of genetic ancestry that reflects continuous variation and historical depth.

Genetics 123

Genetics Medicine Research 123

BioSpace

JULY 11, 2022

Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.

Genetics 95

Genetics Gene Expression Medicine Engineer 95

Bio Pharma Dive

DECEMBER 15, 2020

The acquisition marks a significant bet by Lilly on gene therapy's potential to address tough-to-treat neurological disorders like Parkinson's disease.

Gene Therapy 304

Gene Therapy Genetics Medicine Gene 304

Bio Pharma Dive

MARCH 23, 2023

The biotech plans to use Generation Bio’s nonviral delivery technology to get nucleic acid-based therapies to immune cells and into the liver.

Genetics 156

Genetics Medicine 156

Pharmaceutical Technology

NOVEMBER 8, 2022

Fulgent Genetics has acquired clinical-stage therapeutics development firm Fulgent Pharma for a total deal price of nearly $100m. According to the deal, the purchase price, contingent on adjustments, has to be paid by Fulgent Genetics as a combination of cash on hand and its shares of common stock.

Genetics 130

Genetics Development Genome Genomics 130

Drug Discovery World

JUNE 19, 2024

New research has uncovered how different people respond to sepsis based on their genetics, which could lead to the development of targeted therapies. In the future, this approach to personalised medicine could also be applied to other less severe infections, not just sepsis.

Genetics 64

Genetics Immune Response Genome Genomics 64

Pharmaceutical Technology

FEBRUARY 13, 2023

SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. This collaboration aims to use the global SOPHiA DDM platform, a cloud-native platform of SOPHiA GENETICS, and multimodal algorithmic capabilities for AstraZeneca’s oncology portfolio.

Genetics 130

Genetics Development Drugs Genome 130

Bio Pharma Dive

APRIL 25, 2024

“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

Gene Editing 294

Gene Editing Gene Genetics Medicine 294

Scienmag

JULY 26, 2021

Collaboration signifies strong commitment by all stakeholders to maintain the journal’s high standards and expand its global prominence Credit: ACMG New York, July 26, 2021 – The American College of Medical Genetics and Genomics (ACMG), the only nationally recognized US medical professional organization solely dedicated to improving health (..)

Genetics 98

Genetics Genome Genomics Medicine 98

Pharmaceutical Technology

MAY 25, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The first patients will have their genetic makeup sequenced in Spring 2024 and this data will be shared in 2025.

Biobanking 130

Biobanking Genetics Genome Project Genome 130

Drug Discovery World

MAY 19, 2023

Sania Therapeutics, a new company focused on developing genetic medicines for neural circuit dysfunction, has launched at the American Society of Gene & Cell Therapy (ASGCT) conference. The post New company will focus on genetic medicines for neural circuit dysfunction appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Medicine Gene Development 52

Pharmaceutical Technology

JUNE 8, 2023

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130

Genome Genomics Medicine Development 130

Medical Xpress

MAY 8, 2023

An exhaustive cost-benefit analysis of population genetic testing published in Annals of Internal Medicine concludes with a recommendation to U.S. health policymakers to adopt routine testing of adults ages 40 and under for three genetic conditions posing high risk of life-threatening illness.

Genetics 98

Genetics Medicine 98

Outsourcing Pharma

FEBRUARY 24, 2022

The pharmaceutical companyâs Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a âstate-of-the-artâ facility.

Genetics 52

Genetics Medicine Development RNA 52

Roots Analysis

JANUARY 19, 2024

Introduction In a strategic move to accelerate the development and launch of genetic medicines, BridgeBio Pharma has successfully secured up to USD 1.25 Billion to Propel Genetic Medicine Development appeared first on Blog. billion from Blue Owl Capital and Canada Pension Plan Investment Board.

Genetics 40

Genetics Medicine Development Sales 40

pharmaphorum

FEBRUARY 15, 2024

Gene-editing biotech Prime Medicine has priced an initial public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge, Massachusetts-based company is offering 19.2 million shares at $6.25

Medicine 92

Medicine Gene Editing Genetics Gene 92

Pharmaceutical Technology

JUNE 20, 2023

The Department of Health Abu Dhabi (DoH) has signed a memorandum of understanding with integrated healthcare company M42 and AbbVie Biopharmaceuticals to advance personalised medicine and genomics in the city. M42 was created through the combination of Mubadala Health and G42 Healthcare.

Medicine 130

Medicine Genome Genomics Clinical Trials 130

Pharmaceutical Technology

JULY 7, 2022

Genetic mutations, both germline and acquired, are behind a large proportion of the most debilitating and sometimes life-threatening human diseases. But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Bio Pharma Dive

JANUARY 24, 2024

An 11-year-old boy born deaf can hear after receiving Lilly's genetic medicine. Others, including biotechs in China and Regeneron in the U.S., are taking aim at the same drug target.

Gene Therapy 287

Gene Therapy Gene Genetics Medicine 287

Bio Pharma Dive

DECEMBER 8, 2023

million, while a competing genetic medicine also cleared Friday is priced at $3.1 Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2

Gene Therapy 294

Gene Therapy Gene Genetics Medicine 294

BioPharma Reporter

MAY 18, 2023

Sania Therapeutics, a new biotech company focused on developing genetic medicines for neural circuit dysfunction, has launched by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.

Medicine 97

Medicine Genetics Gene Development 97

Scienmag

JULY 1, 2022

Curing debilitating genetic diseases is one of the great challenges of modern medicine. During the past decade, development of CRISPR technologies and advancements in genetics research brought new hope for patients and their families, although the safety of these new methods is still of significant concern.

Genetics 97

Genetics Genetic Disease Medicine Development 97

Pharmaceutical Technology

FEBRUARY 27, 2024

Making therapies feasible from biological, regulatory, and commercial standpoints drives scalable genetic medicine.

Gene Therapy 246

Gene Therapy Gene Genetics Medicine 246

Drug Discovery World

JANUARY 23, 2024

Sano Genetics, a software company working to accelerate precision medicine research, has raised $11.4 billion, rising to $4.62bn for non-precision oncology medicines. This is why the average R&D for a new precision oncology drug is $3.53

Medicine 52

Medicine Genetics Clinical Trials Clinical Trials 52

STAT News

MARCH 14, 2023

Saying genetics researchers inconsistently and inappropriately use racial and ethnic labels that fail to capture the complex patterns of human genetic variation, the National Academies of Sciences, Engineering, and Medicine issued a report Tuesday calling for a transformation in how such descriptors are used.

Genetics 98

Genetics Research Genome Genomics 98

pharmaphorum

FEBRUARY 15, 2024

Gene-editing biotech Prime Medicine has priced its IPO, hoping to raise $140m to advance its pipeline of one-shot therapies for severe genetic disorders.

Gene Editing 64

Gene Editing Gene Medicine Genetics 64

Bio Pharma Dive

OCTOBER 3, 2023

The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.

Gene Editing 256

Gene Editing In-Vivo Gene Genetics 256

Bio Pharma Dive

JUNE 15, 2023

Lilly will pay the genetic medicine specialist $60 million upfront to work together on a treatment targeting a risk factor known as Lp(a).

Gene Editing 310

Gene Editing Gene Genetics Medicine 310

BioPharma Reporter

JULY 20, 2023

PrecisionLife, a computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Genetics 75

Genetics Medicine Development 75

Bio Pharma Dive

MAY 6, 2024

The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies.

Genetics 171

Genetics Gene Medicine Development 171

Medical Xpress

DECEMBER 7, 2022

Genetic predisposition to attention-deficit/hyperactivity disorder (ADHD) can predict cognitive decline and Alzheimer's disease later in life, revealed an analysis published today in Molecular Psychiatry by University of Pittsburgh School of Medicine researchers.

Genetics 98

Genetics Medicine Research 98